POS1196 COVID-19 VACCINE WILLINGNESS IN RA? RESULTS FROM THE RA LOUVAIN BRUSSELS COHORT

Background: Over 2 million deaths from the COVID-19 disease have been reported in world. Since no antiviral treatment is available, vaccination most important option to fight SARS-CoV-2 infection. Patients living with rheumatoid arthritis (RA) affecting immune system or under immunosuppressive agent will be considered as a high risk population and start shortly. But many patients could decline vaccine for several reasons including safety concerns. Objectives: The aim of this study evaluate proportion RA who are favourable vaccination, know analyse characteristics these patients. Methods: We included UCLouvain Brussels cohort met ACR/EULAR 2010 classification criteria. A simple standard questionnaire was distributed attended rheumatology out patient day care clinic 14 december 20 januari 21. All (Age, gender, education, smoking habits, duration, ACPA, RF, DAS28-CRP, HAQ therapies) were collected at same time. Results: Data 460 eligible analyzed. average age 58.21 years. 72% women. 21% smokers 65% positive anti-citrullinated protein antibody (ACPA) mean DAS28-CRP 2.39 0.821. 281 (61%) indicated they would receive soon it available. For 179 (39%) decline, not having trust time (53%), fear side effects (28%), opposition (4%), previous infection (2%) unknown (5%), Interestingly, there differences among willing vaccine. Patient 50, women, low education grade, smokers, presence RF/ACPA bioDMARD less No observed (see Table 1). 1. Characteristics correlation between groups. TOTAL n=460 VACCIN-YES n=281 (61% ) VACCIN-NO n=179 (39% Age, mn 58,21 +/-0,71 60,37 ± 0,9004 54,82 1,090 p=0.0001* Group Age <30 yrs 25 (5%) 15 10 (6%) =31-50 112 (24%) 53 (19%) 59 (33% =51-70 209 (45%) 127 82 (46%) > 70 114 (25%) 86 (31% 28 (16%) p=0.0003** Gender, F/M, %-F 332/128 (F-72%) 193/88 (F-69%) 139/40 (F-78% p=0.043** Educ0-1 63 (15%) 27 (11% 36 (22%) Educ2-3 349 (85%) 222 (89%) (78% p=0.003** Disease duration yrs, 14,77 +/-0,51 15,24 +/-0,69 14,04 +/-0,73 Smokers: YES/NO/Ex-Smokers, %-YES 85/248/79 (21%) 42/156/52 (17%) 43/92/27 (27% p=0.018** RF YES/NO, % 243/137 (64%) 133/94 (59%) 110/43 (72% p=0.009** ACPA 244/132 (65%) 127/93 (58%) 117/39 (75% p=0.001** HAQ, 0,814+/-0,039 0,797+/-0,051 0,838+/-0,061 2,39+/-0,05 2,35+/-0,07 2,44+/-0,09 GC, 360/86 217/55 (20%) 143/31 (18%) csDMARDs (MTX), 124/322 (72%) 72/200 (74%) 52/122 (70%) BioDMARDs, NO/YES, 151/295 (66%) 107/165 44/130 (*) - Unpaired t Test; (**) Fisher’s exact test Conclusion: In our cohort, rates willingness promising. Dedicated outreach efforts should developed, especially some subpopulation. Disclosure Interests: None declared.